Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Target Raised at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND) had its target price boosted by Cantor Fitzgerald from $300.00 to $315.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Several other equities analysts have also weighed in on ASND. TD Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Sunday, November 8th. Jefferies Financial Group dropped their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. Nineteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $313.52.

Ascendis Pharma A/S Price Performance

ASND stock opened at $275.39 on Friday. The company has a market cap of $17.18 billion, a PE ratio of 18.00 and a beta of 0.40. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The stock has a 50-day moving average price of $242.67 and a two-hundred day moving average price of $239.83. Ascendis Pharma A/S has a 12-month low of $188.08 and a 12-month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a return on equity of 44.80% and a net margin of 73.26%. As a group, research analysts predict that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Avior Wealth Management LLC purchased a new stake in shares of Ascendis Pharma A/S in the third quarter worth about $1,193,000. Frazier Life Sciences Management L.P. grew its stake in shares of Ascendis Pharma A/S by 68.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock valued at $60,053,000 after buying an additional 91,822 shares in the last quarter. Orbimed Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 5.8% in the first quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock valued at $41,624,000 after buying an additional 10,000 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Ascendis Pharma A/S by 1,105.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 17,305 shares of the biotechnology company’s stock valued at $3,943,000 after buying an additional 15,870 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 28,468.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,428 shares of the biotechnology company’s stock valued at $1,237,000 after buying an additional 5,409 shares during the period.

Key Ascendis Pharma A/S News

Here’s some of the latest news about ASND:

• Positive Sentiment: Q3 results and commercial growth were strong. Ascendis reported revenue of $418.7 million, above analyst expectations, while product revenue reached €366 million, up 89% year over year. YORVIPATH accounted for €291 million of product sales. The company also reported a quarterly profit, marking a shift toward commercial-scale profitability. Ascendis Pharma Q3 2026 results
• Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.
• Negative Sentiment: Employee warrants may cause modest dilution. Ascendis granted 28,030 employee warrants, creating a potential increase in shares outstanding if exercised. Read More.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.